Latest News and Press Releases

GHENT, Belgium, June 09, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...

GHENT, Belgium, June 01, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...

RED DESERT data of all patients confirm: alfapump DSR is highly effective at managing fluid and sodium balance in diuretic-resistant heart failure patients without need for loop diuretics...

GHENT, Belgium, April 27, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...

GHENT, Belgium, March 25, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid...

POSEIDON – positive interim results in Q4 2020; additional interim results expected inQ2 2021 and primary endpoint in Q2 2022RED DESERT – positive interim results in Q4 2020; top-line data expected in...

GHENT, Belgium, March 10, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...

GHENT, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid...

GHENT, Belgium, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease,...

GHENT, Belgium, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant...